CEC // Clinical Trials Centre

 

Industry Sponsored Clinical Trials

 

Diabetic Macular Edema

 

☛ An Open Label, Registry Study of the Safety of ILUVIEN® 190 Micrograms Intravitreal Implant in Applicator (IRISS)

ClinicalTrials.gov nº NCT01998412

 

☛ An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME) (VIOLET – BAY 86-5321/17613)

EudraCT nº 2014-004938-25

 

☛ A phase III, multicentre, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (Rhine)

EudraCT nº 2017-005105-12

 

☛ A two-year, three-arm, randomized, double-masked, multicentre, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)

EudraCT nº 2017-004742-23

 

Age-Related Macular Degeneration

☛ An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) (AZURE)

EudraCT nº 2012-003763-22

 

 

Glaucoma

☛ Long-Term Surveillance Study of Latanoprost to Monitor Hyperpigmentation changes in the eye in Pediatric Populations

(A6111144)

 

Neurological Disorders

☛ A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis (EXPAND)

EudraCT nº 2012-003056-36

 

☛ A randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in Mild Alzheimer´s Disease Dementia (DAYBREAK – I8D-MC-AZET)

EudraCT nº 2015-005625-39

 

Cancer

☛ A randomized , open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.

EudraCT nº 2016-004340-11

  

Investigator Initiated Research

 

☛ STAR – Development of a Model for Advanced Screening for Timely Treatment of Age-Related Eye Diseases

 

Diabetic Retinopathy

☛ PROGRESS -Progression of Diabetic Retinopathy. Identification of signs and surrogate outcomes

ClinicalTrials.gov nº NCT03010397

 

☛ CORDIS – Characterization of retinal vascular disease in eyes with mild to moderate Nonproliferative diabetic retinopathy in Diabetes type 2, using novel non-invasive imaging methods, in a longitudinal and prospective clinical study with 2 years of duration

Portugal 2020 – 02/SAICT/2017 – Project nº 030375